Unknown

Dataset Information

Dexpramipexole improves bioenergetics and outcome in experimental stroke.


ABSTRACT:

Background and purpose

Dexpramipexole, a drug recently tested in patients with amyotrophic lateral sclerosis (ALS,) is able to bind F1Fo ATP synthase and increase mitochondrial ATP production. Here, we have investigated its effects on experimental ischaemic brain injury.

Experimental approach

The effects of dexpramipexole on bioenergetics, Ca2+ fluxes, electrophysiological functions and death were evaluated in primary neural cultures and hippocampal slices exposed to oxygen-glucose deprivation (OGD). Effects on infarct volumes and neurological functions were also evaluated in mice following proximal or distal middle cerebral artery occlusion (MCAo). Distribution of dexpramipexole within the ischaemic brain was evaluated by means of mass spectrometry imaging.

Ke

SUBMITTER: Muzzi M 

PROVIDER: S-EPMC5758384 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature